Users Online: 1456 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
 

 

Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
     
Year : 1990  |  Volume : 34  |  Issue : 1  |  Page : 20-34

The current status of diarrhoea related vaccines.


National Institute of Cholera and Enteric Diseases, Calcutta

Correspondence Address:
S K Sarkar
National Institute of Cholera and Enteric Diseases, Calcutta

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 1966245

Rights and PermissionsRights and Permissions

Since diarrhea is responsible for considerable morbidity and mortality in India as well as in developing and developed countries, public health specialists strive to develop vaccines against various pathogens which cause diarrhea. Rotavirus (RV) causes 20-40% of severe diarrhea among 6-24 month olds. So they hope for a single dose vaccine against all 4 RV serotypes which can be administered to newborns, but such a vaccine does not yet exist. The bovine and rhesus vaccines are the only heterologous candidate vaccines available, (as of the end of 1989). Another candidate vaccine is the human-animal reassortant RV vaccine where scientists incorporate the VP7 surface protein of human RV into animal RV. The 3rd type of RV candidate vaccine include the naturally attenuated human RV (nursery strains). Vibrio cholerae also causes significant diarrhea in India. Researchers have conducted field trials of many cholera vaccines since the mid 1990s, but they could not find a vaccine which could be used for mass vaccination against cholera. In fact, the cholera vaccine currently used only provides 50% protection, lasts 3-6 months, does not affect carriers, and does not protect against all strains. Salmonella typhi also causes diarrhea, especially among school age children and young adults. The results of large scale field trials in the 1960s reveal that 2 doses of the acetone inactivated typhoid vaccine performed the best of the injectable killed whole cell vaccines. In fact, it provides 79-93% protection and lasts 3-4 years. Further the live oral Ty21a lyophilized vaccine reconstituted in a liquid form and given in multiple doses provides comparable protection (71-96%) against typhoid as well as some protection against paratyphoid. Moreover they induce no side effects. Shigella species also cause diarrhea, especially in children. Various candidate vaccines against shigellosis include the spontaneously attenuated vaccines, streptomycin dependent vaccines, toxoid against exotoxins, and mutant hybrid strains.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed279    
    Printed13    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 1    

Recommend this journal